An eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Patients With Metastatic...

Area of Science:

• Oncology
• Genetics
• Digital Health

Background:

• Germline BRCA1/2 testing is standard for cancer risk, screening, and PARP inhibitor eligibility.
• PARP inhibitors are approved for metastatic breast, ovarian, pancreatic, and prostate cancers, increasing testing indications.
• Many at-risk patients lack access to genetic services, leading to unidentified genetic carriers.

Purpose of the Study:

• The eREACH study evaluates an eHealth (digital) alternative to traditional genetic counseling for cancer genetic testing.
• It assesses the effectiveness of this digital intervention for patients with metastatic breast, ovarian, pancreatic, or prostate cancer.
• The goal is to determine if digital delivery is a viable option for identifying candidates for PARP inhibitors.

Main Methods:

• A randomized noninferiority study (2x2 design) comparing a digital intervention to standard genetic counseling.
• Participants with metastatic cancers received either full counseling, mixed counseling/digital, or full digital intervention.
• Primary outcomes measured were changes in genetic knowledge and anxiety from baseline to post-disclosure.

Main Results:

• Enrollment of 229 participants was completed by January 2025.
• Data analysis is ongoing, with results anticipated in 2025.
• The study will determine if the digital intervention is noninferior to standard care.

Conclusions:

• There is a growing need for alternative genetic testing delivery models to improve access and uptake.
• The eREACH study assesses an interactive, patient-centered digital intervention for clinical genetic testing in metastatic cancer.
• Findings are expected to inform guidelines and the standard of care for genetic testing delivery, with potential broader applicability.